Drugs / Xisomab 3G3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03097341 | Jun 2017 → Jan 2018 | thrombotic disease | Aronora, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04465760 | Feb → Oct 2021 | plasma cell myeloma | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xisomab 3G3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04465760 ↗ |
| Action | Inhibit | “blocks factor XIIa-mediated FXI activation” PMID 30700130 ↗ Apr 2019 |
| Route | Intravenous | “single intravenous dose of 0.1 mg/kg xisomab 3G3” NCT03097341 ↗ |